Cardiac-Targeted Extracellular Vesicles for Delivery of Therapeutic Nucleic Acids

Abstract

Cardiac-targeted extracellular vesicles (EVs) have emerged as a promising platform for the delivery of therapeutic nucleic acids to the heart, potentially revolutionizing the management of cardiovascular diseases. This review synthesizes current evidence on the application of cardiac-targeted EVs for nucleic acid delivery, outlining their mechanistic advantages, clinical relevance, and translational implications. We discuss the epidemiological burden of cardiac disorders, the pathophysiological rationale for nucleic acid therapies, and the innovative use of EVs as delivery vehicles. Furthermore, we examine risk factors, clinical features, diagnostic approaches, and existing as well as emerging management strategies, integrating recent advances and guideline recommendations. The review concludes with expert insights into future directions for cardiac-targeted EVs in precision medicine.

Introduction

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, necessitating novel therapeutic strategies to address the unmet clinical need. The development of gene-based therapies, including small interfering RNAs (siRNAs), microRNAs (miRNAs), and antisense oligonucleotides, offers the potential to modulate disease at the molecular level. However, effective and specific delivery to cardiomyocytes and other cardiac cells poses substantial challenges. Extracellular vesicles, naturally occurring nanocarriers released by virtually all cell types, have gained attention for their ability to encapsulate and deliver nucleic acids to target tissues with high specificity. Cardiac-targeted EVs, engineered or naturally enriched for heart tissue tropism, represent a paradigm shift in the precision delivery of nucleic acid therapeutics for cardiac diseases.

Epidemiology / Disease Burden

The global burden of heart disease is staggering, with ischemic heart disease, heart failure, and arrhythmias accounting for millions of deaths annually. Despite advances in pharmacotherapy and interventional cardiology, many patients progress to end-stage disease, highlighting the limitations of current treatments. The World Health Organization estimates that over 17.9 million people die from CVDs each year, representing 31% of all global deaths. The increasing prevalence of risk factors such as diabetes, hypertension, obesity, and an aging population further fuels the epidemic, emphasizing the urgent need for innovative, disease-modifying therapies.

Pathophysiology

Cardiac disorders often arise from complex pathophysiological cascades involving genetic, epigenetic, and environmental factors. Central to the disease process are maladaptive remodeling, apoptosis, fibrosis, and inflammation within the myocardium. Nucleic acid-based therapies aim to modulate these pathological pathways by silencing deleterious genes, restoring deficient microRNAs, or correcting specific mutations. However, the myocardium's unique architecture, dynamic blood flow, and robust cellular barriers present obstacles to effective nucleic acid delivery, necessitating innovative delivery systems with high specificity and efficiency.

Risk Factors

Major risk factors for cardiac diseases include age, male gender, hypertension, dyslipidemia, smoking, diabetes mellitus, sedentary lifestyle, and family history of premature CVD. Additionally, genetic predispositions and environmental factors contribute to disease onset and progression. Patients with multiple risk factors often exhibit more aggressive disease phenotypes and poorer responses to standard therapies, making them potential candidates for advanced molecular interventions such as nucleic acid-based therapeutics delivered via EVs.

Clinical Features

Cardiac diseases manifest with a broad spectrum of clinical features, ranging from asymptomatic subclinical dysfunction to overt heart failure, arrhythmias, angina, and sudden cardiac death. Early-stage disease may present with nonspecific symptoms such as fatigue or exertional dyspnea, whereas advanced disease often leads to volume overload, reduced ejection fraction, and multi-organ complications. Accurate characterization of clinical phenotypes is essential for tailoring nucleic acid therapies and optimizing EV-based delivery strategies.

Diagnosis

Diagnosis of cardiac diseases relies on a combination of clinical assessment, electrocardiography, echocardiography, cardiac biomarkers, advanced imaging modalities, and sometimes genetic testing. Recent advances in molecular diagnostics, including circulating microRNAs and cell-free DNA, offer enhanced sensitivity and specificity for early detection and monitoring of disease progression. These molecular signatures also guide the selection and monitoring of nucleic acid-based interventions, providing a framework for precision medicine approaches utilizing EVs.

Treatment & Management

Conventional management of cardiac diseases includes lifestyle modification, pharmacological agents (e.g., beta-blockers, ACE inhibitors, statins), device therapy (e.g., ICDs, pacemakers), and surgical interventions. Despite their efficacy, these modalities do not address the underlying molecular derangements. Nucleic acid-based therapeutics hold promise for targeting the root causes of cardiac pathology. However, their clinical utility is limited by challenges in stability, immunogenicity, and tissue-specific delivery. EVs, with their inherent biocompatibility and ability to traverse biological barriers, are being developed as carriers for targeted cardiac nucleic acid delivery, potentially overcoming these obstacles.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the engineering and application of cardiac-targeted EVs. Strategies include modifying EV surface proteins to enhance cardiac tropism, loading therapeutic RNAs or DNAs via electroporation or transfection, and utilizing stem cell-derived EVs for innate reparative properties. Preclinical studies demonstrate that EV-mediated delivery of miR-126, miR-21, and other cardioprotective miRNAs can attenuate ischemic injury, reduce fibrosis, and improve cardiac function in animal models. Clinical translation is underway, with early-phase trials assessing the safety and efficacy of EV-based therapeutics in patients with myocardial infarction and heart failure. Furthermore, advances in EV isolation, characterization, and large-scale production are facilitating their transition from bench to bedside.

Guideline Recommendations

While no current cardiology guidelines specifically endorse EV-mediated nucleic acid delivery, major societies such as the American Heart Association and European Society of Cardiology highlight the importance of research into novel molecular therapies. Emerging recommendations stress the need for rigorous preclinical validation, standardized manufacturing protocols, and robust clinical trials to establish safety, efficacy, and long-term outcomes. As the field matures, future guidelines will likely incorporate EV-based strategies into the armamentarium of precision cardiovascular medicine.

Conclusion

Cardiac-targeted extracellular vesicles represent a transformative approach for the delivery of therapeutic nucleic acids, offering the potential to address unmet clinical needs in the management of cardiovascular diseases. By combining molecular precision with tissue-specific targeting, EV-based therapies could redefine the treatment paradigm for heart disease. Continued research, multidisciplinary collaboration, and adherence to evolving regulatory frameworks will be essential to realize the promise of these innovative nanocarriers in clinical practice.